Related references
Note: Only part of the references are listed.Bioactive modulators targeting STING adaptor in cGAS-STING pathway
Xi Feng et al.
DRUG DISCOVERY TODAY (2020)
The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer
John Kwon et al.
CANCER DISCOVERY (2020)
Attenuation of cGAS/STING activity during mitosis
Brittany L. Uhlorn et al.
LIFE SCIENCE ALLIANCE (2020)
STING, DCs and the link between innate and adaptive tumor immunity
Ralph E. Vatner et al.
MOLECULAR IMMUNOLOGY (2019)
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Roman M. Chabanon et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Maxim Shevtsov et al.
FRONTIERS IN ONCOLOGY (2019)
The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death
Christian Zierhut et al.
CELL (2019)
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
Timo Reislander et al.
NATURE COMMUNICATIONS (2019)
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC
Triparna Sen et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells
Pepijn M. Schoonen et al.
MOLECULAR ONCOLOGY (2019)
Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Claire Vanpouille-Box et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine
Hiro Sato et al.
CANCER SCIENCE (2019)
cGAS/STING axis mediates a topoisomerase II inhibitor induced tumor immunogenicity
Zining Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Harnessing innate immunity in cancer therapy
Olivier Demaria et al.
NATURE (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The Intriguing History of Cancer Immunotherapy
Paula Dobosz et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Targeting the replication stress response in cancer
Josep V. Forment et al.
PHARMACOLOGY & THERAPEUTICS (2018)
SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-κB and interferon pathways
Shuliang Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
TANK-Binding Kinase 1-Dependent Responses in Health and Autoimmunity
Cynthia Louis et al.
FRONTIERS IN IMMUNOLOGY (2018)
SAMHD1 acts at stalled replication forks to prevent interferon induction
Flavie Coquel et al.
NATURE (2018)
Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response
Assaf Marcus et al.
IMMUNITY (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Kelsey E. Sivick et al.
CELL REPORTS (2018)
The DNA damage response in immunotherapy and radiation
Robert M. Samstein et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Surface Toll-like receptor 3 expression in metastatic intestinal epithelial cells induces inflammatory cytokine production and promotes invasiveness
Marit Bugge et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Immune Diseases Associated with TREX1 and STING Dysfunction
Nan Yan
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2017)
RAD51 interconnects between DNA replication, DNA repair and immunity
Souparno Bhattacharya et al.
NUCLEIC ACIDS RESEARCH (2017)
Combining radiotherapy with immunotherapy: the past, the present and the future
Evert J. Van Limbergen et al.
BRITISH JOURNAL OF RADIOLOGY (2017)
Neurologic Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutieres Syndrome and Beyond
John H. Livingston et al.
NEUROPEDIATRICS (2016)
Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase
Joanne Wayne et al.
ONCOTARGET (2016)
Human Disease Phenotypes Associated With Mutations in TREX1
Gillian I. Rice et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2015)
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
Remi Buisson et al.
MOLECULAR CELL (2015)
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design
Andrew J. Massey et al.
ONCOTARGET (2015)
Roles of Chk1 in cell biology and cancer therapy
Youwei Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Amy B. Hall et al.
ONCOTARGET (2014)
Safeguard against DNA sensing: the role of TREX1 in HIV-1 infection and autoimmune diseases
Maroof Hasan et al.
FRONTIERS IN MICROBIOLOGY (2014)
Human three prime exonuclease TREX1 is induced by genotoxic stress and involved in protection of glioma and melanoma cells to anticancer drugs
Maja T. Tomicic et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Recent insights into the complexity of Tank-binding kinase 1 signaling networks: The emerging role of cellular localization in the activation and substrate specificity of TBK1
Elizabeth Helgason et al.
FEBS LETTERS (2013)
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
New roles for the major human 3′-5′ exonuclease TREX1 in human disease
David Kavanagh et al.
CELL CYCLE (2008)
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
J Bartkova et al.
NATURE (2005)
Share Paper
